treatment in active relapsing remitting multiple sclerosis : A - PowerPoint PPT Presentation

Mar 30, 2024 •184 likes •280 views

Efficacy of alemtuzumab treatment in active relapsing remitting multiple sclerosis : A study of real world evidence ------------------------------ Mentor: Dr. Ofir Zmira Student: Alex Halpern Multiple Sclerosis Alemtuzumab Monoclonal

Efficacy of alemtuzumab treatment in active relapsing remitting multiple sclerosis : A study of real world evidence ------------------------------ Mentor: Dr. Ofir Zmira Student: Alex Halpern
Multiple Sclerosis
Alemtuzumab  Monoclonal Anti CD-52 antibody https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286943/
Previous Studies Citation: N Engl J Med 2008; 359:1786-1801
Study Design  Prospective cohort of 35 ARRMS patients  Variables followed:  1. EDSS  2. Relapse rate  3. Number and volume of MRI lesions
Results
Results P=.6177
Results Number of MRI lesions (Gadolinium) Number of MRI lesions
 Questions?

Download Presentation

Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

Audit on Use of Fingolimod in Treatment of Relapsing-Remitting MS in University Hospitals

Audit on Use of Fingolimod in Treatment of Relapsing-Remitting MS in University Hospitals Coventry and Warwickshire Omar Salim ST5 Neurology Aims To assess the real world experience of Fingolimod use in University Hospitals Coventry

630 views • 27 slides

Treatment guidelines for relapsing MS and the two step approach for disease modifying

Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Klaus Schmierer, PhD FRCP Blizard Institute, Barts and The London School of Medicine & Dentistry Barts Health NHS Trust Disclosures PI of

552 views • 36 slides

BJ's symptoms are most likely consistent with 1. which of the following? Relapsing-remitting MS

C ASE P RESENTATION Maya Zeineddine, Pharm D Multiple Sclerosis Certified Specialist American University of Beirut Medical Center March 19, 2016 Amman, Jordan BJ is a 28-year-old white woman in the clinic for evaluation of significant

504 views • 26 slides

Disclosures SDN: participated in scientific advisory boards for Biogen Idec and Genzyme;

Consortium of Multiple Sclerosis Centers 2014 Annual Meeting Dallas, TX Immunogenicity with Peginterferon Beta-1a: 2-year Data from the ADVANCE Study in Relapsing-Remitting Multiple Sclerosis Scott D. Newsome, DO May 30, 2014 Scott D.

369 views • 9 slides

Visual system in MS Optic neuritis (ON): Inflammatory demyelination of the optic nerve.

6/9/2014 Multifocal Visual Evoked Potentials (mfVEP) and Ganglion Cell Inner Plexiform Thickness (GCIPT) in Relapsing Remitting Multiple Sclerosis (RRMS) Divya Narayanan, Han Cheng, Rosa Tang, Laura Frishman University of Houston Houston, TX

590 views • 12 slides

A big ig data approach for understanding environmental ri risk factors for autoimmune dis

A big ig data approach for understanding environmental ri risk factors for autoimmune dis isease fl flare Brian Reddy Trinity Health Kidney Centre / ADAPT Autoimmune disease affects 15% of the population Relapsing and Remitting

368 views • 17 slides

Diagnosis of Active TB Proper diagnostic evaluation is essential before anticipating any treatment

Active TB Section 6: Diagnosis of TB (Latent vs. Active Disease) Diagnosis of Active TB Proper diagnostic evaluation is essential before anticipating any treatment for active TB disease because the risk of unnecessary or inadequate treatment can

338 views • 3 slides

HALT MS: Study Overview Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation

Five Year Outcomes of Halt MS: High Dose HALT MS: Study Overview Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Severe Relapsing Remitting Multiple Sclerosis Hypothesis : Intensive immunosuppressive

359 views • 7 slides

Cognitive Constructs and the Intent to Remit: Are Norms the Key to Explaining Remitting Behaviour

Cognitive Constructs and the Intent to Remit: Are Norms the Key to Explaining Remitting Behaviour of Kosovar Migrants in Germany Wiebke Meyer and Judith Mllers (Leibniz Institute of Agricultural Development in Central and Eastern Europe) and

583 views • 14 slides

OUR VISION For all patients around the world to have access to quality treatment for the chronic

RBP-6000 B UPRENORPHINE M ONTHLY D EPOT P HASE III C LINICAL R ESULTS RBP-6000 I NVESTOR E VENT J UNE 29 TH , 2017 Our vision is that all patients around the world will have access to quality treatment for the chronic relapsing conditions and

645 views • 29 slides

NUTRITION DURING CANCER TREATMENT TODAYS OUTLINE Eating Healthfully During Cancer Treatment

NUTRITION DURING CANCER TREATMENT TODAYS OUTLINE Eating Healthfully During Cancer Treatment The Nourishing Plate Supplement use considerations during active treatment Staying Hydrated During Cancer Treatment Food Safety

1.01k views • 37 slides

TREATMENT OF ACTIVE LUPUS NEPHRITIS WITH VOCLOSPORIN: RAPID REMISSION OVER 48 WEEKS: DATA FROM

TREATMENT OF ACTIVE LUPUS NEPHRITIS WITH VOCLOSPORIN: RAPID REMISSION OVER 48 WEEKS: DATA FROM THE AURA-LV STUDY SV Parikh 1 , WF Pendergraft 2 , JA Tumlin 3 , R Saxena 4 , N Solomons 5 , RB Huizinga 5 The Ohio State University Wexner Medical

566 views • 32 slides

$New Approach to the Presbyopia Treatment Introduction Tri-ED EDOF Concepts Active Diffractive$

New Approach to the Presbyopia Treatment Introduction Tri-ED EDOF Concepts Active Diffractive

New Approach to the Presbyopia Treatment Introduction Tri-ED EDOF Concepts Active Diffractive Optic Semi-Apodized Optic True TriFocality All in One Platform Technical Specifications First Clinical Results Competition Product Segmentation

471 views • 33 slides

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA 2017-040 5/2/17 Eileen Tonner, MS Purpose of the Study For patients who have received curative-intent prostate cancer treatment Determine whether

537 views • 21 slides

Phase III studies of direct oral anticoagulants for treatment and prevention of VTE Dabigatran,

Phase III studies of direct oral anticoagulants for treatment and prevention of VTE Dabigatran, apixaban, edoxaban and rivaroxaban Phase III VTE acute treatment studies Trial name Design Initial treatment Treatment Long-term Active with

709 views • 19 slides

The Active Card An Active Mind in an Active Body More people, More Active, More often! The

The Active Card An Active Mind in an Active Body More people, More Active, More often! The Active vision Active The Olympic Legacy 100,000 card holders by 2012 SMART card technology Improved communications for

421 views • 21 slides

The proposed new NHS England MS Prescribing Guidelines will stop the current wide variation in

The proposed new NHS England MS Prescribing Guidelines will stop the current wide variation in DMT prescribing across England. Yes! Dr David Paling Royal Hallamshire Hospital, Sheffield NIHR Sheffield Biomedical Research Centre Translational

709 views • 43 slides

A Revolution inMind June 2020 LegalDisclaimers This presentation contains forward-looking

A Revolution inMind June 2020 LegalDisclaimers This presentation contains forward-looking statements, including statements about: uncertainties regarding the FDA regulatory approval process, including whether the results of our clinical trials

842 views • 17 slides

Motor Radiculopathy An Unusual Presentation of Multiple Sclerosis J.H. NOSEWORTHY and L.P.M.

LEJOURNALCANADIENDES SCIENCES NEUROLOGIQUES Motor Radiculopathy An Unusual Presentation of Multiple Sclerosis J.H. NOSEWORTHY and L.P.M. HEFFERNAN SUMMARY: A 28 year old female INTRODUCTION presented with clinical and electrical When

484 views • 3 slides

Women, Wisconsin & Multiple Sclerosis Colleen G. Kalt President & CEO National MS

Women, Wisconsin & Multiple Sclerosis Colleen G. Kalt President & CEO National MS Society-Wisconsin Chapter History of the National MS Society: Sylvia Lawry Our Mission Mobilize people and resources to drive research for a cure and to

513 views • 15 slides

A causal approach to changing the course of neurodegenerative diseases January 2020 Disclaimer

A causal approach to changing the course of neurodegenerative diseases January 2020 Disclaimer This presentation has been prepared by GeNeuro solely for use in the context of a general information meeting. All persons accessing this document

822 views • 60 slides

Jo Groves Chief Executive Officer IMDRF-3 Stakeholder Forum 20 March 2013 Nice, France

Promoting patient-centred healthcare around the world International Regulatory Convergence: Meeting Patients Needs Jo Groves Chief Executive Officer IMDRF-3 Stakeholder Forum 20 March 2013 Nice, France Promoting patient-centred healthcare

479 views • 16 slides

CENTURY Jane Sacco, Chief Division of Long Term Care Services Office of Health Services GOALS

PASRR FOR THE 21ST CENTURY Jane Sacco, Chief Division of Long Term Care Services Office of Health Services GOALS OF PASRR FOR THE 21ST CENTURY By the end of this session, participants will have a greater understanding of how PASRR is to be

871 views • 45 slides

HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against

HARNESSING THE POWER OF THE INNATE IMMUNE SYSTEM Modulating an Innate Immune Response Against Diseases INMB INVESTOR PRESENTATION 2Q20 V1 FORWARD LOOKING STATEMENTS This presentation contains forward -looking statements Forward-looking

903 views • 47 slides